Skip to main content

Table 1 Inclusion and exclusion criteria for entering the PAHFRAC-01 clinical trial

From: Ferric carboxymaltose with or without erythropoietin for the prevention of red-cell transfusions in the perioperative period of osteoporotic hip fractures: a randomized contolled trial. The PAHFRAC-01 project

Age ≥65 years Bone marrow diseases which could interfere in the erythropoietic process (acute or chronic myelodysplastic syndromes or myeloproliferative diseases, and/or infiltration of the bone marrow due to solid or lymphatic neoplasm)
Osteoporotic hip fracture requiring surgical repair Blood coagulation diseases or being currently treated with oral anticoagulants and/or heparin at therapeutic doses.
Hemoglobin levels between 90-120 g/L Documented allergy and/or previous intolerance and/or contraindication of erythropoietin use and/or intravenous iron
Signed informed consent form Patients with rheumatoid arthritis and/or another demonstrated origin of inflammatory anemia and/or not controlled arterial hypertension
  Patients with current or previous treatment for at least 3 months, with erythropoietin or intravenous iron
  Patients with chronic renal failure receiving hemodialysis or peritoneal dialysis